The University of Texas M. D. Anderson Cancer Center

Receive alerts:
by e-mail
E-mail Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L. I have read and accept the Terms of Use
via RSS

2.962 documents for The University of Texas M. D. Anderson Cancer Center

- American Airlines/Susan G. Komen for the Cure[R] Promise Grant to the University of Texas M. D. Anderson Cancer Center Enables Much Progress in First Year.
Inflammatory Breast Cancer Grant Helps Fund Four Potential Novel Therapeutic Agents DALLAS -- Since receiving the first American Airlines Susan G. K...
- Business Wire
- October 15, 2009
- New Book Chronicles the Journeys of Women Physicians and Scientists to the Front Lines of Fighting Cancer
To: NATIONAL EDITORS Contact: Tomise Martin, +1-713-792-9518, tdmartin@mdanderson.org, or Laura Sussman, +1-713-745-2457, lsussman@mdanderson.org, both of The University of Texas M. D. Anderson Cancer Center
- U.S. Newswire
- March 20, 2009
- ImmunoCellular Therapeutics Enters into Option Agreement with The University of Texas M. D. Anderson Cancer Center for a Novel Cancer Stem Cell Therapy.
LOS ANGELES -- ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) (IMUC), a biotechnology company that is focused on the development of novel immune-base...
- Business Wire
- December 02, 2009

- Bio-Path Holdings, Inc. Announces Plans to Develop Liposome Tumor Targeting Technology Licensed from The University of Texas M. D. Anderson Cancer Center.
Liposome Targeting Technology and Planned Sponsored Research Program May Produce Sustainable Advantages in the Treatment of Cancer and Other Diseases ...
- Business Wire
- September 22, 2009
- Hitachi ''PROBEAT'' Proton Beam Therapy System Now Online Treating Patients at the University of Texas, M. D. Anderson Cancer Center.
BRISBANE, Calif. -- Hitachi, Ltd. (NYSE:HIT) and its subsidiary, Hitachi America, Ltd., today announced the successful startup of the company's "PROBE...
- Business Wire
- June 30, 2006
- Callisto Announces Licensing of a New Class of Cancer Drugs With a Novel Mechanism of Action, Showing Potent Antitumor Activity; Drug Class Developed at The University of Texas M. D. Anderson Cancer Center.
NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX: KAL)(FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health...
- Business Wire
- January 25, 2006
- BayPoint Biosystems Acquires Exclusive Commercial Rights to Proteomic Patent Portfolio from the University of Texas M. D. Anderson Cancer Center.
HOUSTON -- BayPoint Biosystems Inc., a privately held personalized medicine company, announced today that it has entered into a technology licensing a...
- Business Wire
- March 27, 2008
- The University of Texas M. D. Anderson Cancer Center Enters into Joint Development with Applied MEMS.
HOUSTON -- Development of Key Technology for Next-Generation Bio-Chemical Analyzers The University of Texas M. D. Anderson Cancer Center and Applied...
- Business Wire
- September 20, 2004
- February: National Cancer Prevention Month
Cancer is a very confusing disease because it cannot be defined as one specific symptom. When you have shingles or strep throat, chicken pox or the flu, there are specific symptoms and specific ways to cure them. The University of Texas M. D. Anderson Cancer Center describes cancer as, "a large and complex family of malignancies that can affect virtually every organ in the body." Cancer is the second largest killer in the United States after heart disease, with over 1 million new cases diagnosed each year, and is predicted to overtake the #1 spot by 20 1 0. Cancer isn't specific to any age, race, or gender and can strike at any time. Cancer is most often characterized by tumors. Benign tumors are not cancerous and are not fatal but can cause problems with health relating to their size a...
- Culvert Chronicles, The
- September 02, 2009
- ChemGenex Licenses Targeted Platinum IV Compound from the University of Texas M. D. Anderson Cancer Center.
MELBOURNE, Australia & MENLO PARK, Calif. -- New molecule is active in cancer cells resistant to existing platinum II agents ChemGenex Pharmaceutica...
- Business Wire
- February 09, 2005